Liquidia

Liquidia Corporation

Enhancing drug delivery to the lungs to make every breath count

Founded in 2004, **LIQUIDIA CORPORATION** (NASDAQ: LQDA) is a biopharmaceutical company dedicated to the development and commercialization of best-in-class therapies with the potential to improve the standard of care for patients with different pulmonary diseases.

Leveraging our PRINT® Technology, we aim to improve drug delivery to the lungs and reduce the burden of administration so patients can breathe easier and live longer.

Liquidia Corporation operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) that is currently under FDA review. Liquidia Technologies is also developing L606, an investigational liposomal formulation of treprostinil administered twice-daily with a short-duration next-generation nebulizer. Liquidia PAH provides the commercialization for pharmaceutical products to treat pulmonary disease, such as generic Treprostinil Injection.

MISSION STATEMENT

We are difference makers driven to help patients with pulmonary hypertension breathe easier and live longer. Each of us is committed to act daily towards our mission to change patients' lives for the better by enhancing drug delivery to the lungs and making every breath count.

CORE VALUES

- **Mission-Driven Execution:** committed to achieving the highest standards with a tenacious pursuit of excellence
- **Adaptive Agility:** Embracing a lean and flexible approach to swiftly respond and effectively make things happen
- **Courageous Innovation:** Continuously challenging the norm, actively seeking and considering novel ideas to drive improvement and overcome obstacles
- **Teamwork & Ethical Integrity:** Prioritizing trust, collaboration, and ethical practices in all our endeavors

Strategically positioned to drive significant market presence in rapidly expanding pulmonary hypertension market

EXECUTIVE LEADERSHIP

Roger Jeffs
Chief Executive Officer

Dr. Rajeev Saggar
Chief Medical Officer

Michael Kaseta
Chief Operations Officer and Chief Financial Officer

Scott Moomaw
Chief Commercial Officer

Jason Adair
Chief Business Officer

PLATFORM

PRINT® Technology

- Precise, uniform drug particles
- Enhanced delivery to the deep lung
- Broad applicability

An example of the precise particle engineering enabled by PRINT is demonstrated in YUTREPIA™ (treprostinil) inhalation dry powder. Each particle is designed to enhance delivery and deep-lung penetration with a precise size and highly uniform shape inspired by a naturally occurring pollen. YUTREPIA PRINT particles have a one micrometer trefoil shape. In vitro studies suggest that the uniformity of size and shape allow our inhaled particles to target delivery into the lungs with less deposition in the upper airways, reducing adverse side effects.

PRODUCTS

YUTREPIA™ (treprostinil) inhalation dry powder

- Tentatively approved by FDA for PAH in November 2021
- Submitted amended NDA for PAH and PH-ILD in July 2023
- Awaiting final FDA action letter on amended NDA

Treprostinil Injection

- PAH: generic Remodulin® for parenteral administration
- Co-promoted by Liquidia in partnership with Sandoz

PIPELINE

L606 sustained-release inhaled treprostinil

- Less frequent dosing (2x daily)
- Improved tolerability with lower peak exposures
- Sustained drug exposure over 24 hours
- Rapid delivery with next-generation nebulizer
- Currently in Phase 3 Open-Label U.S. study (NCT04691154)
- Planning global Phase 3 pivotal study in PH-ILD for 2024

PAH and PH-ILD Represent Attractive Markets with Unmet Need

Pulmonary hypertension (PH) occurs when blood pressure within the lungs becomes abnormally elevated because of thickening of the pulmonary artery walls in PAH patients or scarring of lung tissue caused by interstitial lung disease in PH-ILD patients

Pulmonary Arterial Hypertension (PAH)

- PAH is a rare, chronic, progressive disease caused by hardening and narrowing of the pulmonary arteries that can lead to right heart failure and eventually death
- Currently, an estimated 45,000 patients are diagnosed and treated in the United States[1]
- The 3-year survival rate for patients with PAH is 75%[2]

Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

- PH-ILD includes a diverse collection of up to 150 different pulmonary diseases, including interstitial pulmonary fibrosis, chronic hypersensitivity pneumonitis, connective tissue disease related ILD, and chronic pulmonary fibrosis with emphysema (CPFE) among others.
- Any level of PH in ILD patients is associated with poor 3-year survival (~35%)[3]
- A current estimate of PH-ILD prevalence in the United States is greater than 60,000 patients[1], though population growth in many of these underlying ILD diseases is not yet known

There is currently no cure for PAH or PH-ILD, so the goals of existing treatments are to alleviate symptoms, maintain or improve functional class, delay disease progression, and improve quality of life

Inhaled treprostinil is the only medication approved to treat both PAH and PH-ILD.

For more information or to contact Liquidia:

419 Davis Drive, Suite 100, Morrisville, NC 27560
Tel +1 919-328-4400 • Fax +1 919-328-4402

liquidia.com

linkedin.com/company/liquidia-corporation

x.com/liquidia_corp

Sources
1. CVrg Market Strategies™ 2Q 2023
2. Boucly et al, *Am J Respir Crit Care Med.* 2021 Oct 1;204 (7):842-854
3. Piccari et al, *Respiration* 2022;101:717–727 725

Liquidia

US-LIQ-2300018 08-24